CASI

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics addressing cancer and other diseases with significant unmet medical needs in China and throughout the world. Headquartered in Rockville, Maryland, the company operates with a strategic focus on the Chinese pharmaceutical market while maintaining global development capabilities. CASI's portfolio includes product candidates in various stages of clinical development and commercialization, targeting hematologic malignancies and solid tumors. The company's business strategy emphasizes in-licensing or acquiring rights to novel drug candidates developed elsewhere and advancing them through clinical trials and regulatory approval processes in China and other markets. CASI has established partnerships with pharmaceutical companies and research organizations to access innovative therapies and expand its product pipeline. The company's commercial operations in China leverage local market expertise and relationships with healthcare providers to maximize product uptake. CASI Pharmaceuticals conducts clinical trials to evaluate the safety and efficacy of its drug candidates and works closely with regulatory authorities including China's National Medical Products Administration. The company aims to bring transformative treatments to patients in markets where access to advanced cancer therapies has historically been limited.